Stocks making the biggest moves premarket: Novo Nordisk, JPMorgan Chase, United Airlines & more

Novo Nordisk rose 3% on an OpenAI partnership, while JPMorgan, J&J, and BlackRock all beat first-quarter expectations on EPS and/or revenue. JPMorgan still fell 2% after lowering net interest income guidance, and Wells Fargo slipped 1% on a mixed quarter; J&J shares were up about 0.9% and BlackRock gained 1.7% on beats. United Airlines rose 2% and American Airlines more than 4% on merger chatter, while Intel added 1% as it neared a 10-session winning streak.

Analysis

The cleanest read-through is that markets are rewarding companies that can convert narrative into operating leverage, while penalizing anything that introduces duration or balance-sheet uncertainty. Novo’s AI partnership matters less as a branding event than as a signal that pharma is moving from batch R&D to workflow automation; the second-order winner is likely the contract research and data-tool ecosystem, while incumbents with large, manual clinical pipelines may see margin pressure if AI meaningfully shortens cycle times. In healthcare, that creates a dispersion trade rather than a broad sector bid.

Banks are telling a more fragile macro story. JPM’s beat is being treated as backward-looking because the market immediately focused on the NII reset; that usually means investors are starting to discount peak earnings quality, not just absolute earnings. If rates drift lower or loan growth stays muted, the downside to consensus for large deposit-rich banks can persist for 1-2 quarters even if credit stays benign. Wells’ softer reaction reinforces that the Street wants cleaner operating leverage, not just accounting-driven EPS beats.

BlackRock and the airlines point to a market that still wants cyclicals with idiosyncratic catalysts, but is highly sensitive to guidance credibility. For airlines, merger chatter is more useful as a valuation reset than as an imminent event; the immediate trade is that AAL can outperform on optionality, while UAL’s relative move may fade if antitrust scrutiny looks nontrivial. Intel’s streak is technically interesting but fundamentally fragile: if momentum is driven by short covering rather than improving earnings power, the stock can remain bid for days to weeks before the market demands proof in margins or foundry execution.

Key Decisions for Investors

• Buy NVO on pullbacks vs a basket of large-cap pharma suppliers/contract research names for a 1-3 month momentum-plus-productivity trade; upside comes if the market extrapolates AI-led operating leverage, while risk is that the announcement proves to be a sentiment catalyst only.
• Short JPM vs long XLF peers with more rate-beta protection for the next 1-2 quarters; the risk/reward favors fading the beat if NII downgrades continue, since the stock can rerate lower even with stable credit.
• Long BLK on 3-6 month horizon versus WFC as a cleaner capital-markets proxy; BLK has better operating leverage to equity-market risk assets, while WFC remains vulnerable to guidance skepticism and muted deposit economics.
• Trade AAL call spreads or a small tactical long vs UAL for 2-8 weeks; the setup is asymmetric if merger speculation sustains, but cap the position because antitrust and integration realities can unwind the move quickly.
• Fade INTC strength only after a failed breakout day; use a short-dated put spread if the stock loses momentum, since the current move appears technically driven and the downside can reassert once the streak narrative exhausts.